Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$114.22 - $140.1 $14,391 - $17,652
-126 Reduced 4.72%
2,541 $352,000
Q4 2023

Feb 28, 2024

SELL
$75.49 - $124.16 $14,871 - $24,459
-197 Reduced 6.88%
2,667 $330,000
Q3 2023

Nov 22, 2023

SELL
$86.06 - $137.93 $1.26 Million - $2.02 Million
-14,646 Reduced 83.64%
2,864 $267,000
Q2 2023

Aug 14, 2023

BUY
$112.47 - $130.98 $701,362 - $816,791
6,236 Added 55.31%
17,510 $2.25 Million
Q1 2023

Jun 05, 2023

BUY
$104.0 - $122.92 $1.17 Million - $1.39 Million
11,274 New
11,274 $1.31 Million
Q4 2022

Jun 12, 2023

SELL
$84.98 - $122.67 $797,452 - $1.15 Million
-9,384 Reduced 83.24%
1,890 $214,000
Q2 2022

Aug 11, 2022

BUY
$67.99 - $132.89 $222,395 - $434,683
3,271 Added 289.73%
4,400 $328,000
Q1 2022

May 20, 2022

SELL
$94.08 - $130.2 $470 - $651
-5 Reduced 0.44%
1,129 $578,000
Q4 2021

Feb 17, 2022

BUY
$129.87 - $162.82 $57,272 - $71,803
441 Added 63.64%
1,134 $609,000
Q3 2021

Nov 23, 2021

SELL
$106.71 - $143.18 $37.8 Million - $50.7 Million
-354,347 Reduced 99.8%
693 $379,000
Q3 2021

Nov 16, 2021

BUY
$106.71 - $143.18 $37.8 Million - $50.7 Million
354,319 Added 49142.72%
355,040 $379,000
Q2 2021

Aug 24, 2021

SELL
$80.99 - $107.93 $2,267 - $3,022
-28 Reduced 3.74%
721 $308,000
Q1 2021

May 17, 2021

BUY
$84.79 - $104.74 $13,481 - $16,653
159 Added 26.95%
749 $269,000
Q4 2020

Feb 18, 2021

BUY
$78.0 - $104.5 $2,496 - $3,344
32 Added 5.73%
590 $218,000
Q3 2020

Nov 17, 2020

BUY
$95.51 - $112.95 $3,820 - $4,518
40 Added 7.72%
558 $230,000
Q2 2020

Aug 14, 2020

BUY
$62.68 - $105.34 $32,468 - $54,566
518 New
518 $210,000
Q1 2020

May 18, 2020

SELL
$47.79 - $75.63 $50,800 - $80,394
-1,063 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$36.62 - $57.29 $38,927 - $60,899
1,063 New
1,063 $233,000

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $30.2B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track This Portfolio

Track Ep Wealth Advisors, LLC Portfolio

Follow Ep Wealth Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ep Wealth Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ep Wealth Advisors, LLC with notifications on news.